MX376449B - Composición inmunoterapeutica novedosa y usos de la misma. - Google Patents

Composición inmunoterapeutica novedosa y usos de la misma.

Info

Publication number
MX376449B
MX376449B MX2016003363A MX2016003363A MX376449B MX 376449 B MX376449 B MX 376449B MX 2016003363 A MX2016003363 A MX 2016003363A MX 2016003363 A MX2016003363 A MX 2016003363A MX 376449 B MX376449 B MX 376449B
Authority
MX
Mexico
Prior art keywords
ara
composition
immunotherapeutic composition
allergy
present
Prior art date
Application number
MX2016003363A
Other languages
English (en)
Spanish (es)
Other versions
MX2016003363A (es
Inventor
Jennifer May Rolland
Robyn Elizabeth O'hehir
Sara Rachel Prickett
Original Assignee
Aravax Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903686A external-priority patent/AU2013903686A0/en
Application filed by Aravax Pty Ltd filed Critical Aravax Pty Ltd
Publication of MX2016003363A publication Critical patent/MX2016003363A/es
Publication of MX376449B publication Critical patent/MX376449B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
MX2016003363A 2013-09-25 2014-09-25 Composición inmunoterapeutica novedosa y usos de la misma. MX376449B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013903686A AU2013903686A0 (en) 2013-09-25 Novel immunotherapeutic composition and uses thereof
PCT/AU2014/050249 WO2015042664A1 (en) 2013-09-25 2014-09-25 Novel immunotherapeutic composition and uses thereof

Publications (2)

Publication Number Publication Date
MX2016003363A MX2016003363A (es) 2016-09-23
MX376449B true MX376449B (es) 2025-03-07

Family

ID=52741648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003363A MX376449B (es) 2013-09-25 2014-09-25 Composición inmunoterapeutica novedosa y usos de la misma.

Country Status (11)

Country Link
US (3) US11266737B2 (https=)
EP (2) EP3049098A4 (https=)
JP (1) JP7007534B2 (https=)
KR (1) KR20160075532A (https=)
CN (2) CN105992589A (https=)
AU (2) AU2014328483B2 (https=)
BR (1) BR112016006813A2 (https=)
MX (1) MX376449B (https=)
RU (1) RU2689552C2 (https=)
WO (1) WO2015042664A1 (https=)
ZA (1) ZA201602043B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
EP3938053A4 (en) * 2019-03-13 2023-03-22 Psomagen, Inc. EPITOP-BASED APPROACH TO ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE
US20240042016A1 (en) * 2020-12-30 2024-02-08 The Regents Of The University Of Michigan Nanoemulsion vaccine compositions and methods for suppressing reactivity to multiple food allergens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
EP0873135B1 (en) 1995-12-29 2009-07-22 The University of Arkansas Peanut allergens and methods
US6835824B1 (en) * 1995-12-29 2004-12-28 University Of Arkansas Peanut allergens and methods
US20030202980A1 (en) 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
GB2348808B (en) 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
DE69921773D1 (de) 1998-01-16 2004-12-16 Univ Johns Hopkins Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe
AU743647B2 (en) 1998-01-31 2002-01-31 Mt. Sinai School Of Medicine Of New York University Methods and reagents for decreasing allergic reactions
AU3085299A (en) 1998-03-12 1999-09-27 Board Of Trustees Of The University Of Arkansas, The Tertiary structure of peanut allergen ara h 1
AU3717600A (en) 1999-03-02 2000-09-21 Board Of Trustees Of The University Of Arkansas, The Methods and reagents for decreasing clinical reaction to allergy
WO2000051647A2 (en) 1999-03-03 2000-09-08 Mount Sinai School Of Medicine Of New York University Animal model of allergies
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
AU2065801A (en) 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
US20020147140A1 (en) 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
RU2285042C2 (ru) 2000-11-16 2006-10-10 Альк-Абелло А/С Новые мутантные аллергены
ATE414773T1 (de) 2000-11-16 2008-12-15 Alk Abello As Mutante allergene
AU2002306850A1 (en) 2001-03-16 2002-10-03 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
MXPA03010037A (es) 2001-05-01 2004-06-30 Univ California Moleculas de fusion y metodos para tratamiento de enfermedades inmunes.
EP1453539B1 (en) 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
CA2499123A1 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
US8057800B2 (en) * 2004-06-10 2011-11-15 Circassia Limited Immunointeractive molecules and uses thereof
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
FI20075063A0 (fi) * 2007-02-01 2007-02-01 Vactech Oy Allergisen herkistymisen estäminen
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
GB2455108A (en) 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
EP2140880B1 (en) 2008-07-04 2012-11-14 HAL Allergy Holding B.V. Modification of allergens
EP2331124A1 (en) 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2478373B1 (en) 2009-09-14 2019-01-09 Icahn School of Medicine at Mount Sinai Methods for characterizing antibody binding affinity and epitope diversity in food allergy
WO2011106645A1 (en) 2010-02-26 2011-09-01 Benaroya Research Institute Direct analysis of antigen-specific immune response
US8835361B2 (en) 2010-06-01 2014-09-16 The Curators Of The University Of Missouri High-throughput quantitation of crop seed proteins
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20140080730A1 (en) 2011-03-20 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Method for predicting severity of allergic reaction
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
JP2013040138A (ja) 2011-08-17 2013-02-28 Univ Of Tsukuba 活性化型リコンビナント花粉アレルゲンの作製方法
WO2013036301A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells for inducing regulatory b cells
CN102533781B (zh) 2011-12-30 2013-09-11 华南师范大学 花生2s-4b蛋白在诱导细胞凋亡中的应用
CN102816232B (zh) 2011-12-30 2014-07-16 华南师范大学 花生2s-4b蛋白及其生产方法
CA2861003C (en) 2012-01-13 2023-03-28 Julius-Maximilians-Universitat Wurzburg Dual antigen-induced bipartite functional complementation
AU2012382406B2 (en) 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
DK2914285T3 (en) 2012-11-01 2017-02-27 Veterinærinstituttet New fusion proteins for the treatment of allergic diseases
MY193724A (en) 2013-03-15 2022-10-27 Sementis Ltd Immune modulation
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof

Also Published As

Publication number Publication date
US11266737B2 (en) 2022-03-08
AU2020200883B2 (en) 2022-05-12
AU2020200883A1 (en) 2020-02-27
RU2016115732A (ru) 2017-10-30
US20220280637A1 (en) 2022-09-08
ZA201602043B (en) 2022-08-31
JP7007534B2 (ja) 2022-01-24
WO2015042664A1 (en) 2015-04-02
RU2016115732A3 (https=) 2018-06-19
EP4710935A3 (en) 2026-05-06
US20160375130A1 (en) 2016-12-29
CN105992589A (zh) 2016-10-05
EP3049098A1 (en) 2016-08-03
US11986522B2 (en) 2024-05-21
CN121714673A (zh) 2026-03-24
AU2014328483A1 (en) 2016-04-21
AU2014328483B2 (en) 2019-11-14
CA2925480A1 (en) 2015-04-02
RU2689552C2 (ru) 2019-05-28
EP4710935A2 (en) 2026-03-18
JP2016533341A (ja) 2016-10-27
BR112016006813A2 (pt) 2017-09-19
US20240415955A1 (en) 2024-12-19
EP3049098A4 (en) 2017-08-16
MX2016003363A (es) 2016-09-23
KR20160075532A (ko) 2016-06-29

Similar Documents

Publication Publication Date Title
WO2016172658A3 (en) Microbiome regulators and related uses thereof
SG10201811454WA (en) Materials and methods for controlling infections
EA201390559A1 (ru) Подавление иммунного ответа по типу гиперчувствительности неродственным антигеном, получаемым из материала-источника аллергенов
WO2015143046A3 (en) Methods and compositions for regulation of zinc finger protein expression
EP4357355A3 (en) Virus purification
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2015085318A3 (en) Targeted adaptive vaccines
MX2017003535A (es) Anticuerpos anti-glucagon y sus usos.
EA202090948A1 (ru) Иммуномодуляция
MX379275B (es) Polvo de coleopteros.
WO2015136287A3 (en) Compositions and methods relating to the treatment of diseases
EP4218736A3 (en) Compositions comprising 15-hepe
EA201791416A1 (ru) Популяции клеток rpe и способы их получения
PH12019502469A1 (en) Novel fragrance compositions and products with mood enhancing effects
GB201118201D0 (en) Novel peptides
MX376449B (es) Composición inmunoterapeutica novedosa y usos de la misma.
PH12016501159B1 (en) Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
EP4501949A3 (en) Pneumolysin mutants and methods of use thereof
WO2015022077A8 (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
PH12018500201A1 (en) Enhanced immune response in porcine species
WO2018081183A3 (en) Maca compositions and methods of use
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2020012569A (es) Moleculas inmunoterapeuticas novedosas y sus usos.
MY188028A (en) Sialylated glycoprotein compositions and uses thereof
WO2015095789A3 (en) Suppression of allergic lung inflammation and hyperreactivity

Legal Events

Date Code Title Description
FG Grant or registration